AVEO Oncology inks deal with BMS to study kidney cancer combo

12 March 2021
aveo_oncology_large

Hot on the heels of gaining US Food and Drug Administration approval for its lead candidate Fotivda (tivozanib), US biotech AVEO Oncology (Nasdaq: AVEO) says it has entered into a clinical trial collaboration and supply agreement with US pharma major Bristol Myers Squibb (NYSE: BMY).

The aim is to evaluate Fotivda in combination with BMS’ blockbuster anti-PD-1 therapy Opdivo (nivolumab), in the pivotal Phase III TiNivo-2 trial in patients with relapsed or refractory renal cell carcinoma following prior immunotherapy exposure.

The news was welcomed, as the FDA approval of Fotivda was based on a clinical trial comparing it with what was viewed an obsolete drug, at best showing no overall survival advantage, and pushed AVEO’s shares up 6.6% to $12.65 in morning trading today.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology